TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com - New Avugane™ data in the two groups of patients receiving 3% and 6% doses support further clinical development - Copenhagen, Denmark - 13 March 2009 - TopoTarget A/S (OMX: TOPO) has announced that treatment with topical Avugane™ gel (valproic acid) 3% and 6% gave encouraging results in patients with acne vulgaris. Although the changes in the counts of the acne lesions did not reach statistically significant differences between the three treatment groups (0.5%, 3%, and 6%) in this small study, the overall assessment both by the investigators and the patients did demonstrate a trend towards more favourable effect in the 3% group. The original protocol had the 6% Avugane™ treatment as the target treatment and it was unfortunate that stability problems prevented a study of this probably optimal concentration. However the short treatment provided to six patients with the 6% Avugane™ did show promising results particularly of the inflammatory lesions. All three grades of the Avugane™ gels were very well tolerated. The trend in the efficacy assessment report supports a trial of a new and more stable formulation of 6% Avugane™. TopoTarget intends to outlicense the drug to a partner with expertise in the dermatological field. “Although this study supports our previous positive valproic acid results in acne there are still a formulation tasks to solve with this product. We are focusing on belinostat and have stopped our dermatology activities and we hope to outlisence the use of valproic acid for skin diseases,” says professor Peter Buhl Jensen, CEO of TopoTarget. “In addition to the opportunity of using valproic acid in dermatology it is exciting to see that there are 17 investigators initiatiated clinical trials ongoing in cancer using valproic acid. These trials are not sponsored by TopoTarget but we do have a strong patent protection in the use of valproic acid in cancer and we look forward to seeing the results of these studies”, Peter Buhl Jensen further comments. TopoTarget A/S For further information, please contact: Peter Buhl Jensen Telephone +45 39 17 94 99 CEO Mobile +45 21 60 89 22